CD20 Monoclonal Antibody (L26), eFluor™ 615, eBioscience™, Invitrogen™

Description

• Description: The monoclonal antibody L26 recognizes human CD20, a two transmembrane spanning protein found on precursor and mature B lymphocytes
• Expression is lost upon differentiation to plasma cells
• The levels of CD20 are critical in evaluating maligt B lymphocytes including Non-Hodgkin's Lymphoma, and Acute B cell, Chronic Lymphocytic and Hairy-Cell Leukemias
• CD20 plays a role in B cell differentiation and activation
• The structure of the protein shows a small extracellular loop with the carboxy and amino termini in the cytoplasmic compartment
• The L26 antibody recognizes an epitope in the cytoplasmic domain and therefore requires permeabilization of the tissue for staining applications
• Unlike many anti-CD20 antibodies that recognize the extracellular domain, the epitope recognized by L26 will not be blocked by therapeutic antibodies to CD20, like Rituximab
• Applications Reported: This L26 antibody has been reported for use in immunohistochemical staining of formalin-fixed paraffin embedded (FFPE) tissue sections (IHC-P)
• Applications Tested: This L26 antibody has been tested immunohistochemistry on FFPE human tonsil with low pH antigen retrieval
• It is recommended that this antibody be carefully titrated for optimal performance in the assay of interest
• This product has not been validated for flow cytometric analysis
• CD20 is a non-glycosylated surface phosphoprotein that has a molecular weight range of 33-37 kDa depending on the degree of phosphorylation
• CD20 is expressed on mature and most malignant B cells, in a subpopulation of T lymphocytes and follicular dendritic cells
• CD20 expression on B cells is synchronous with the expression of surface IgM and it regulates transmembrane calcium conductance, cell cycle progression and B-cell proliferation
• CD20 is also associated with lipid rafts, but the intensity of this association depends on extracellular triggering, employing CD20 conformational change, and/or BCR (B cell antigen receptor) aggregation
• After the receptor ligation, BCR and CD20 colocalize and then rapidly dissociate before BCR endocytosis, whereas CD20 remains at the cell surface
• CD20 serves as a useful target for antibody-mediated therapeutic depletion of B cells, as it is expressed at high levels on most B-cell malignancies, but does not become internalized or shed from the plasma membrane following monoclonal antibody treatment
• Diseases associated with CD20 dysfunction include Ms4a1-related common variable immune deficiency.